Ipca Laboratories, Cadila Healthcare prepares to make drug for coronavirusIllustrative image – not actual.
Hydroxychloroquine (HCQS) is a drug being tested by the US Food and Drug Administration (USFDA) for potential treatment of COVID-19. The drugs major manufacturing players are Indian companies. Ipca Laboratories and Cadila Healthcare are gearing up to meet the demand if required. 
 
Ipca Laboratories is the biggest producer of the drug and Cadila Healthcare, an Ahmedabad-based drug manufacturer too is a major player for manufacturing of the drug. 
 
Both the companies are gearing up to meet the demand. A combination Hydroxychloroquine and Azithromycin is being considered. 
 
Alembic Pharmaceuticals, a Vadodara-based drug manufacturer is the domestic market leader with its brand Azithral, with an almost 30 percent share. 
 
Cadila Healthcare was producing 20 tonne of Hydroxychloroquine per month, and it had started to raise the production. It is geared up to supply enough drug for the Indian market. Also, most of the raw materials used are available locally. 
 
In addition, the country could make 100 tonne of the drug per month immediately. 
 
Apart from this, there is demand for Ipca Laboratories. The USFDA has relaxed the import alert imposed on its plants for the active pharmaceutical ingredient (API) and the finished product of Hydroxychloroquine Sulphate and Chloroquine Phosphate.  
 
APIs for Hydroxychloroquine sulphate and Chloroquine Phosphate are produced at the company’s Ratlam unit in Madhya Pradesh, while the formulation is produced at Pithampur, Madhya Pradesh, and Piparia, Silvassa. 
 
Ipca Laboratories, vertically integrated with capacities and capabilities for manufacturing of these APls and its formulations, is preparing to manufacture and supply these products meeting the stringent cGMP, quality and regulatory requirements. 
 
The company used to make 600 tonne of Chloroquine Phosphate, an anti-malarial drug, per year. The company had an 80 percent share of the global market. However, the demand for the medicine has reduced with cases relating to malaria variant decreasing. 
 
Apart from this, Alembic Pharmaceuticals has revealed there is enough material to make Azithromycin till June 2020 and supplies from China have started coming.
← All latest storiesBack to top →